新型症状聚类可预测炎症性肠病疾病影响与医疗资源使用:前瞻性纵向随访研究
该研究对692例成人炎症性肠病(IBD)患者基线记录人口学、疾病活动度、焦虑、抑郁及躯体症状评分,其中348例(50.3%)检测粪便钙卫蛋白(FC)。采用潜在类别分析识别症状聚类,并随访6.5年,用多因素Cox回归比较聚类间结局。三聚类模型最优:聚类1(132例,19.1%)胃肠与心理症状低于平均水平,聚类2(352例,50.9%)为平均水平,聚类3(208例,30.1%)两者均最高。与聚类1相比,聚类3的疾病发作或糖皮质激素处方风险显著增加(HR 2.13;95%CI 1.46-3.10),升级治疗(HR 1.92;95%CI 1.34-2.76)、复合终点(升级、住院或肠切除,HR 2.05;95%CI 1.45-2.88)及任一终点(HR 2.06;95%CI 1.45-2.93)风险均显著增加,且医疗资源使用最高。
要点
- 三聚类模型最优:聚类1(132例,19.1%)症状低于平均,聚类2(352例,50.9%)平均,聚类3(208例,30.1%)症状最高。
- 与聚类1相比,聚类3的发作或糖皮质激素处方风险显著增加(HR 2.13;95%CI 1.46-3.10)。
- 聚类3的升级治疗、复合终点及任一终点风险均显著高于聚类1,且医疗资源使用最高。
核心结论
- 基于模型的症状聚类可识别IBD中不良疾病结局风险较高且医疗资源使用量大的患者。
研究设计与样本
- 前瞻性纵向随访研究,纳入692例成人IBD患者,基线记录人口学、疾病活动度、焦虑、抑郁及躯体症状评分。
- 基线时348例(50.3%)患者检测粪便钙卫蛋白(FC),以<250 mcg/g定义生化缓解。
- 采用潜在类别分析基于基线胃肠与心理症状识别患者聚类,随访6.5年,用多因素Cox回归比较聚类间结局。
主要发现
- 三聚类模型最优:聚类1(132例,19.1%)胃肠与心理症状低于平均水平,聚类2(352例,50.9%)两者均为平均水平,聚类3(208例,30.1%)两者均最高。
- 与聚类1相比,聚类3的发作或糖皮质激素处方风险显著增加(HR 2.13;95%CI 1.46-3.10)。
- 与聚类1相比,聚类3的升级治疗风险显著增加(HR 1.92;95%CI 1.34-2.76)。
- 与聚类1相比,聚类3的升级、住院或肠切除复合终点风险显著增加(HR 2.05;95%CI 1.45-2.88),任一终点风险亦显著增加(HR 2.06;95%CI 1.45-2.93)。
- 聚类3的医疗资源使用最高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predicting adverse disease outcomes and high-volume users of healthcare amongst patients with inflammatory bowel disease (IBD) is difficult. AIMS: The aim of this study is to use latent class analysis to create novel clusters of patients and to assess whether these predict outcomes during 6.5 years of longitudinal follow-up. METHODS: Baseline demographic features, disease activity indices, anxiety, depression, and somatoform symptom-reporting scores were recorded for 692 adults. Faecal calprotectin (FC) was analysed at baseline in 348 (50.3%) patients (<250 mcg/g defined biochemical remission). Using baseline gastrointestinal and psychological symptoms, latent class analysis identified specific patient clusters. Rates of glucocorticosteroid prescription or flare, escalation, hospitalisation, or intestinal resection were compared between clusters using multivariate Cox regression. RESULTS: A three-cluster model was the optimum solution; 132 (19.1%) patients had below-average gastrointestinal and psychological symptoms (cluster 1), 352 (50.9%) had average levels of gastrointestinal and psychological symptoms (cluster 2), and 208 (30.1%) had the highest levels of both gastrointestinal and psychological symptoms (cluster 3). Compared with cluster 1, cluster 3 had significantly increased risk of flare or glucocorticosteroid prescription (hazard ratio (HR): 2.13; 95% confidence interval (CI): 1.46-3.10), escalation (HR: 1.92; 95% CI: 1.34-2.76), a composite of escalation, hospitalisation, or intestinal resection (HR: 2.05; 95% CI: 1.45-2.88), or any of the endpoints of interest (HR: 2.06; 95% CI: 1.45-2.93). Healthcare utilisation was highest in cluster 3. CONCLUSIONS: Novel model-based clusters identify patients with IBD at higher risk of adverse disease outcomes who are high-volume users of healthcare.
引用
- Riggott C, Fairbrass KM, Black CJ, et al. Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study. Aliment Pharmacol Ther. 2023. PMID: 37792347. doi:10.1111/apt.17735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。